Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
furaprevir + peg-interferon alfa-2a + ribavirin
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral (furaprevir, Ribavirin), Subcutaneous (peg-interferon Alfa-2a)
01
Overview
A **combination therapy** of **furaprevir** (an investigational NS3 protease inhibitor), **peg-interferon alfa-2a** (a pegylated interferon used as an immunomodulator and antiviral), and **ribavirin** (a nucleoside analogue antiviral), investigated for treatment of **chronic hepatitis C virus (HCV) infection**. - **Furaprevir** inhibits the NS3 serine protease required for HCV polyprotein processing and replication. - **Peg-interferon alfa-2a** enhances host immune response and exerts antiviral effects via interferon-stimulated genes. - **Ribavirin** likely induces lethal mutagenesis in virions and inhibits viral RNA synthesis. This combination would aim for synergistic inhibition of HCV replication across multiple stages and mechanisms, mainly in patients with chronic HCV; furaprevir is not yet widely studied or approved, whereas peg-interferon alfa-2a + ribavirin has established efficacy and approval as a dual therapy.
- Brand names
- Pegasys (for peg-interferon alfa-2a)none known for this specific combination
- Other names
- none known for this exact triple combination
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on furaprevir + peg-interferon alfa-2a + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on furaprevir + peg-interferon alfa-2a + ribavirin.